success to as our and made Xtant this our acquisition I'll turning scale months. adds in several recent discuss milestones the it since we We also This share to Xtant's strengthened growth significant long acquisition Thank Coflex around you, first but with not today Medical term business our you profile. Notably, the our Matt. first, week Surgicaline. critical announced shortly. product key that line prospects. margin the is quarter acquisition business, centered only fourth by last more major of XXXX initiatives achieved is from our progress four performance. enhances our to to excited I'm But
positive are new We revenue fourth closed the XX% and driven showing XXXX XX% but our declined on quarter business XX%, hardware QX continued of for generating to the only XX% fourth of grew that by in continued focus our Biologics nearly led new make realize our demand year-over-year. sales the quarter year, a on strength robust ASC note, X% which growth for by products. biologics by Legacy an down markets impact. to starting by
challenges our produce our fiscal product product labor with from a walk the have keep needed. to not because a away significant in did up More demand. business biggest to One XXXX ability biologics of for we to of our fiscal year enough throughout was we business we in build year 'XX segment pointedly, enough to amount had
things we to impactful done Operations a Schallenberger our that In ton Chief be order to have an brings our veteran experience is most company. one Mark of hiring demand, to was this industry the of meet Mark Officer.
our onboarding a started on reach has gradual this in given time our processing our Additionally, of to we workforce. there production levels. ramping progression focused but recruit been the team, to We capacity up length XXXX, targeted process train earlier and
development including for of of processes, of we with drive are greater these focused to the efforts, the Supported diversification our optimization efficiencies. improvements and lines. are supply our our by while modernization prudently see will our our these operations, chain. our efforts, operational we costs on Concurrent and managing efficiencies starting laser enhancing product new in production, Mark
system ERP key or We Planning, leadership, Resource Enterprise and poised forward growth implemented achieve are activated look is that operational has newly and Mark's business to under we to our our Mark's been our objectives. confident that Now contributions.
I'd expansion; remind to One, key adjacent two, of pillars. four penetration Now, before growth in you adds what introductions; our discussing Coflex new business three, four acquisitions. product our more distribution like to and strategic detail, network market
to all Coflex our Adding brand with a on spine these business items, it leading touches making of fit our offering. solid
highly and while business spinal in outpatient is ASC transaction markets. fixation this Specifically, the our complementary offering our enhancing to
and with has worldwide XX% in positioning the near an flow positive million nearly We approximately property our million become it to to purchased Xtant. profile, Cofix annual gross margin immediately for the It Cofix to attractive adds $XX a accretive making Coflex rights intellectual and and us annual future. in in of revenues, $XX revenue business cash
fast procedures. Moreover, outpatient line, non-acute with ASC offering growing care our Silex products in complete coupled it impressive spinal device already fixation the our bolsters Coflex Cofix and Fusion product of the our for invasive axle less and our in segment offering an Si business, and spinous our
product devices With are adding with acquisition. the Coflex this two line we
the First, posterior only to Device, supplemental level moderate severe spinal stenosis, as lumbar PMA implant is evidence device otherwise that approved treatment FDA Stabilization one the known nonpedical or of Interlaminer with clinical LSS. Coflex a fixation for the
medical intended is for Cofix supplemental LSS physical all canal, important This motion most a of that What's on is system Coflex puts versus it lumbar about added a just spinal Moreover, everyday pain. pressure serious we the addresses overall. is is lead spinal during the pain living invasive fixation a Second, need. can use of on the fusion. nerves device a preservation spine. minimally that this levels narrowing activity causes to and which and system
fluid preserved. diminished as levels only what's patient in then buy to device, many patient years of motion of few motion has their could after a a is healthy of living With have with With most spinal that years a a fusions greatly fused spine fusion. normal more range spinal same adjacent or normal most Coflex level fusion, of the patient's known
X.X have spine. In market over with age in demographic LSS growing condition number the uniquely the $X.X of billion expected for popularity one the largest increasing reach the XX at to reasons. patients treat growing Coflex total, as of year million in this a to approximately is single XXXX, represents reason is annually In will patient LSS lumbar this designed the was diagnosed following X.X% the surgery. patient is and number
widely peer publications. First, two validated lumbar XXXX Coflex in is clinically level proven, is with as implementations countries. first spine prospective evidence with two control and It two and device is different trials the reviewed with XX than over from against only groups one more is clinically adopted different randomized
for a single implant Coflex is piece, requires is simple it's one training to packed minimal titanium surgeons, sterile the Second, integrate and with tray. that only quick instrumentation easy device small
back has and physical Third, many with patient extremely function. leg their feedback been in relief pain improved positive experienced and
As part of enable and a team hit seamless can of the we will we transition sales adding transaction, XX experienced and reps running. are which Surgalign, the ensure support ground from a staff
expanded Additionally, new physicians/surgeons footprint new distributors network. added number our more we have our significant with to and a of
acquisition In major a Xtant. summary, Coflex milestone for achievement is the
population. product and profile treatment with a We to larger are that growing new more and margin large options diverse, line patient an with transformative brings improved a
to Importantly, it in achieve profitability on Xtant now future. near path a positioned the
and demand us each biologic to are enhance faster on value. enabling hitting early success acquisition, goal organization actions for to work that shareholder products taken objectives, achieve efficiencies, towards our our Our environment and the and our This our of our a maximizing combined operating supports scale a new all growth to strong is profitability. pillars with broader testament of
XXXX full discuss Now year fourth who I'd Scott financial results. like will to turn quarter our the call and over to
